Multicenter evaluation of the cepheid xpert xpress SARS-CoV-2/Flu/RSV test

Heba H. Mostafa, Karen C. Carroll, Rachel Hicken, Gregory J. Berry, Ryhana Manji, Elizabeth Smith, Jennifer L. Rakeman, Randal C. Fowler, Mindy Leelawong, Susan M. Butler-Wu, David Quintero, Minette Umali-Wilcox, Robert W. Kwiatkowski, David H. Persing, Fred Weir, Michael J. Loeffelholz

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


With the approach of respiratory virus season in the Northern Hemisphere, clinical microbiology and public health laboratories will need rapid diagnostic assays to distinguish severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from influenza virus and respiratory syncytial virus (RSV) infections for diagnosis and surveillance. In this study, the clinical performance of the Xpert Xpress SARS-CoV-2/Flu/RSV test (Cepheid, Sunnyvale, CA, USA) for nasopharyngeal swab specimens was evaluated in four centers: Johns Hopkins Medical Microbiology Laboratory, Northwell Health Laboratories, NYC Public Health Laboratory, and Los Angeles County/University of Southern California (LAC1USC) Medical Center. A total of 319 nasopharyngeal swab specimens, positive for SARS-CoV-2 (n = 75), influenza A virus (n = 65), influenza B virus (n = 50), or RSV (n = 38) or negative (n = 91) by the standard-of-care nucleic acid amplification tests at each site, were tested using the Cepheid panel test. The overall positive percent agreement for the SARS-CoV-2 target was 98.7% (n = 74/75), and the negative agreement was 100% (n = 91), with all other analytes showing 100% total agreement (n = 153). Standard-of-care tests to which the Cepheid panel was compared included the Cepheid Xpert Xpress SARS-CoV-2, Cepheid Xpert Xpress Flu/RSV, GenMark ePlex respiratory panel, BioFire respiratory panel 2.1 and v1.7, DiaSorin Simplexa COVID-19 Direct, and Hologic Panther Fusion SARS-CoV-2 assays. The Xpert Xpress SARS-CoV-2/Flu/RSV test showed high sensitivity and accuracy for all analytes included in the test. This test will provide a valuable clinical diagnostic and public health solution for detecting and differentiating SARS-CoV-2, influenza A and B virus, and RSV infections during the current respiratory virus season.

Original languageEnglish (US)
Article numbere02955-20
JournalJournal of clinical microbiology
Issue number3
StatePublished - Mar 2021


  • 4-plex
  • Cepheid
  • Flu
  • Influenza
  • RSV
  • SARS-CoV-2

ASJC Scopus subject areas

  • Microbiology (medical)


Dive into the research topics of 'Multicenter evaluation of the cepheid xpert xpress SARS-CoV-2/Flu/RSV test'. Together they form a unique fingerprint.

Cite this